London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Up 14% suddenly!
I reckon it's TwoGood2Die piling in after a change of mind. LOL!
π
"However, most CTCs perish in the circulation, and only limited CTCs survive and infiltrate distant organs. Interactions between CTCs and the blood environment (Fig. 2), including how CTCs escape immune surveillance in the blood, have been widely implicated in the metastatic mechanisms of CTCs. It has taken more than a century for researchers to recognize the critical role of CTCs in cancer metastasis, due to the unique technical challenges required to isolate these very rare CTCs from the massive pool of circulating blood cells15. However, in the past two decades, emerging technologies for CTC isolation have allowed research on the biology of CTCs and have facilitated the clinical applications of CTCs in cancer screening, treatment response monitoring, and prognosis evaluation."
https://www.nature.com/articles/s41392-021-00817-8#:~:text=To%20date%2C%20most%20CTC%20research,be%20the%20substrate%20of%20metastasis.
That's right Emerald, cancer couldn't spread in the first place if the original tumour didn't shed CTC's
Up 10.26%.
Miavoce.
"Emerald, the cancer doesn't need to have spread for CTC analysis to be relevant. All solid tumours release CTC's irrespective of metastatic status.".
=========================
Very interesting. Thanks. You mean if you have cancer that has NOT spread you may have circulating tumour cells in your blood stream? Not good. Did not know that. Means analysis is possible even when the cancer has NOT spread then.
All IMHO.
Up 7.69%.
They may have arrived !
Investing in ANGLE PLC presents a remarkable opportunity for substantial returns, boasting a promising 294.37% upside potential according to analyst ratings and the 12-month average price target of 70.00p. This signifies an outstanding chance for considerable growth and profit.
Hello.
Emerald, the cancer doesn't need to have spread for CTC analysis to be relevant. All solid tumours release CTC's irrespective of metastatic status.
In view of the contracts with both Eisai and now Astrazeneca I'm half expecting Angle to gain another major investor i.e. an investment house building up a stake of several percent. The Eisai contract news on the 2nd of Jan was a relatively small contract. That clearly was insufficient to get another major player on board. However, the RNS of 3rd May, a half million Β£ contract with Astrazeneca, I think will. It's now completely obvious that both these Companies realise monitoring the circulating tumour cells is necessary when conducting a cancer drug trial involving ANY cancer that has metastasised (spread). The market is absolutely MASSIVE. Could become the "Standard procedure" when doing a cancer drug trial involving a cancer that has spread. The implications are mind blowing.
https://www.lse.co.uk/rns/AGL/new-commercial-agreement-with-large-pharma-gvzk9wgh1la0ljx.html
https://www.proactiveinvestors.co.uk/companies/news/1046802/angle-announces-second-assay-with-astrazeneca-as-it-deepens-relationship-with-pharma-giant-1046802.html
All IMHO.
Sheβs a little stuck at the moment, few more buys needed for the next β π. Cannot understand how we are still not at our 52 week high. Time and patience I guess.
Market cap's OVER $15 billion is NOT going to make a bid for Angle Plc?
Angles market cap is just $61 Million (not Billion!).
Any offer would have to be more than the last placing price of ****80p**** a share I think.
Curent sp.......................20.5p ! JOKE!
All IMHO.
Catch and carry out tests on circulating tumour cells in patients with cancer that has matasicised (spread), right? Astrazeneca are ranked 7th in the World, and Eisai 49th largest right? The smallest of the two is Eisai with a market cap of $15 billion. Astras is $212 bilion. So there are ****48 Pharma Plc's with a market cap exceeding $15 billion****.................... This is a "NO BRAINER" if ever there was one. TWOGOOD...... DO YOU UNDERSTAND? Maybe not......
All IMHO.
I concur, this market is just getting started and could be MASSIVE!!
Unfortunately, there is a huge rise in noncommunicable diseases and AGL is in a position to help this unfortunate global trend. Cannot begin to explain how huge AGL is going to be and how important to many people worldwide.
"The increasing prevalence of cancer due to genetic disorders, rising alcohol consumption, and rapid lifestyle changes are key factors driving the market growth. CTC assists in the early identification and real-time monitoring of lung, breast, digestive tract, and prostate cancer. In line with this, the increasing utilization of CTC in patient screening for metastasis and preclinical studies of new cancer drugs is favoring the market growth. Furthermore, the growing demand for minimally invasive (MI) diagnostic procedures and widespread adoption of CTC-based liquid biopsy to enable rapid recovery and limit trauma are providing a considerable boost to the market growth."
https://uk.finance.yahoo.com/news/circulating-tumor-cell-ctc-market-094800931.html
Offering 20.53 to sell at the moment
π oh dear oil, oh dear.
You never know with AGL. Chartwise I expect a bit more of a pull back than to 19p.
And send the Pharma Co the results. Just pay them!
Join Eisai and Astrazeneca while they still have capacity.......! LOL!
Form an orderley queue........
Up 6.9 %
Up 3.85%.
Roll up! Get your circulating tumour cells analysed at Angle Plc during your cancer drug trial. You need the information don't you! Mad not to!
Oil worst timed post ever!
Going into the 20s
Oil you need L2 mate
Up she goes 30s on the way
Blue